Recent Updates
Recently added Catalysts
VNRX Neutral Sentiment

Veterinary Cancer Society 2022 Annual Conference

Wednesday, October 4, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the Veterinary Cancer Society's 2022 Annual Conference, mentioning related press releases from VolitionRx. It highlights a collaboration with Sysmex and a new patent for the Nu.Q® NETs test aimed at Ebola triage and treatment monitoring. However, specific details about the conference are not provided.
Price reaction · baseline $14.572 (2023-10-03 close) · hit pre-market · clean, no other VNRX news in the window
day 0 close · peak
-7.4%
day 1
-3.9%
day 3
-1.8%

Market Sentiment Analysis

Full Press Release Details

Related Articles

• Press Releases VolitionRx Announces Collaboration with Sysmex
• Press Releases VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

VolitionRx Announces Collaboration with Sysmex

VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields
ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Veterinary Cancer Society VolitionRx Sysmex Nu.Q® NETs Test Ebola Treatment
Last updated: Oct 4, 2023

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk